Author: rb809rb

  • What happened to ‘Afghan girl’ 41 years after iconic photo

    What happened to ‘Afghan girl’ 41 years after iconic photo

    In 1985, a teenage girl from Afghanistan would become a global icon, instantly recognisable to millions, and more than 40 years later she has found a new home.

    Sharbat Gula was just 13 years old when her portrait, taken by photojournalist Steve McCurry, was printed on the front cover of National Geographic in 1985, making her face and her piercing eyes instantly recognisable around the world as the ‘Afghan girl’.

    To say that a lot has happened in Afghanistan since 1985 would be an enormous understatement. In 1996, 11 years after the photo was taken, the Taliban would take power for the first time, imposing a brutal regime under their first rule from 1996 until 2001, when the government was pushed out by the US invasion.

    The extremists would remain out of power for 20 years, waging a war of insurgency against coalition forces in Afghanistan until their chaotic withdrawal presented them with an opportunity.

    Sharbat had been living in Pakistan for more than 30 years when she was deported to Afghanistan in 2017, after being arrested for possessing forged identity documents, and was in the country in 2021.

    Sharbat in 2016 (SHAH MARAI/AFP via Getty Images)

    Sharbat in 2016 (SHAH MARAI/AFP via Getty Images)

    When the Taliban launched their offensive that year the Afghan Army waged a courageous and hard-fought campaign against them, but despite the bravery of the Afghan army, without coalition support they were unable to prevent the Taliban from again seizing power.

    They have been in power ever since, running a highly repressive government in which women are particularly targeted by extreme repressive measures.

    As the Taliban approached Kabul, images of people clinging to the wheels of a plane as it took off, only to be seen falling from the sky moments later as the aircraft climbed, have taken on their own chilling significance.

    Sharbat was a widely recognisable face, and as such there was a particular need for her to get out of Afghanistan when the Taliban returned to power, and fortunately she was able to be evacuated to Italy with her family, where she was granted asylum.

    “I had the freedom to choose,” she told Italian newspaper La Repubblica in 2024. “When the Taliban arrived, I understood that it would be difficult for me to stay: I am too well-known.

    The Taliban retook Kabul in 2021, seizing power after 20 years (Wakil KOHSAR / AFP via Getty Images)

    The Taliban retook Kabul in 2021, seizing power after 20 years (Wakil KOHSAR / AFP via Getty Images)

    “Several governments offered me help: I ​​chose Italy. I knew that you [Italy] had done a lot for Afghanistan. I wanted to try.”

    Speaking about her life in Italy, she said: “Everyone is kind here, but we don’t talk to many people because of the language barrier. No one knows who I am, and for me, that’s very pleasant.”

    She added: “For now, only my Italian teacher, my doctor, and a few others know who I am, and that suits me just fine.”

    Sharbat also expressed unhappiness and frustration with the photo, telling the outlet that it ‘created a lot of problems for me’.

    “I would have preferred it had never been taken,” she said. “I remember that day well, that photographer who arrived at the Nasir Bagh camp school.

    “I was a child. I didn’t like photos. In Afghan culture women do not appear in photos. But there wasn’t much choice”

    Sharbat shared that her daughter wants to become a doctor, something that would be impossible in Afghanistan where women are not permitted education beyond primary school.

    “Here we are free, we can choose,” said Sharbat. “My daughter wants to become a doctor: and I promised her that I will do everything I can to make her wish come true.”

  • Bryan Johnson Spent Millions to Reverse Aging. He Says a Filter Works Better

    Bryan Johnson Spent Millions to Reverse Aging. He Says a Filter Works Better

    In brief

    • Bryan Johnson wrote on X that the best anti-aging therapies are filters, retouching and lighting.
    • Since June he has disclosed autoimmune gastritis, a diagnosis for girlfriend Kate Tolo, and a refocus on curing disease.
    • Johnson says he is still aiming for immortality by 2039.

    Bryan Johnson, the face of the “Don’t Die” movement, just posted the least immortal tweet of his career.

    “Sadly, the best anti-aging therapies are filters, retouch and lighting,” the biohacker wrote on X on Tuesday.

    Myriad: Which company will IPO next? Click to make your prediction.
    Myriad: Which company will IPO next? Click to make your prediction.

    That’s an odd line from a man who has said he spends $2 million a year trying to make his body act 18 again. This man has done everything and more in his quest for immortality, from changing his entire habits to weird things like shockwave therapy on his penis.

    So is Johnson giving up and praying the gospel of Botox and makeup? Not exactly. But the summer changed him.

    On June 30, he announced he has autoimmune gastritis, a chronic condition where the immune system attacks the stomach lining. He said he was diagnosed in May.

    Weeks later, his girlfriend and Blueprint co-founder Kate Tolo was diagnosed with endometriosis, plus PMOS and adenomyosis, after about six weeks of testing.

    On July 21, Johnson said he had “cloned” himself as a newborn. A community note disagreed. What he made was induced pluripotent stem cells, which are reprogrammed adult cells and not a clone.

    Then came the pivot. In a July 24 post, Johnson wrote that he nearly shut down his longevity company last year and asked himself what to build on the eve of superintelligence.

    His answer? Cure all diseases. He pointed to GitLab co-founder Sid Sijbrandij, who reported no evidence of disease after going “founder mode” on his cancer. He also cited Paul Conyngham, the Sydney engineer whose custom mRNA vaccine reportedly shrank his dog’s tumors by roughly 75%.

    Johnson said he refocused Immortals, the $1 million-a-year program he launched in February with three slots, on building tools so individuals can find and fix their own health problems. He and Tolo are the first customers.

    The old menu stays: nutrition, GLP-1s, hormones, peptides, biomarkers. New additions include stem cells, organoids, and personalized therapy development.

    BitcoinBTC · USD

    $83,736−1.82%

    Sep 30Oct 2Oct 4Oct 5Oct 7

    $86.8k$85.7k$84.6k$83.4k

    24h HighHigh$86,648

    24h LowLow$83,610

    VolVol$1.6B

    Market projectionsOdds by Myriad

    →

    Then, last month, Johnson posted that “in many ways” he is 18. He listed sleep, fertility, resting heart rate, vascular health and inflammation as indistinguishable from a teenager’s.

    The exceptions were hearing and somatic mutations. He also conceded that he looks his age, 49, which is probably why some botox may beat millions of dollars of medical research to achieve the same results.

    Johnson’s attention/obsession has also moved toward women’s health. Tolo told Australia’s ABC that female health was always “next,” and she is aiming to become the “world’s most measured woman”. The protocol collects 14 million data points on her menstrual cycle.

    Johnson told the same outlet he remains committed to his goal of immortality by 2039, it’s just not his only life goal. The deadline is 13 years away, so he would be an immortal dude in his 60s.

    Probably not how an immortal person would like to look for eternity, but also nothing that some concealer can’t fix.

    Daily Debrief Newsletter

    Start every day with the top news stories right now, plus original features, a podcast, videos and more.

  • Killer Films Boards Ray Panthaki’s Directorial Debut ‘In Starland’ as Feature Lands Tallinn World Premiere (EXCLUSIVE)

    Killer Films Boards Ray Panthaki’s Directorial Debut ‘In Starland’ as Feature Lands Tallinn World Premiere (EXCLUSIVE)

    “In Starland,” the directorial debut of British star Ray Panthaki and led by “Sing Sing” breakout Clarence Maclin, has been backed by some of the indie film world’s leading lights.

    Killer Films has boarded the feature, with Christine Vachon and Mason Plotts having joined the producing team.

    The news comes just as “In Starland” has been announced as world premiering at the 30th Tallinn Black Nights Film Festival, where it has been selected to close the festival’s first feature competition.

    Written by Panthaki and Jason Kavan, “In Starland” is described as a coming-of-middle-age drama which Maclin plays Ernie, a 50-year-old loner whose quiet life is upended when a group of young influencers arrive in his small town and draw him into their chaotic, hyper-connected world, forcing him to confront questions of belonging, identity and the life he has allowed himself to live.

    The ensemble cast also includes Miss Benny (“Club Kid”), Bella Maclean (“Rivals”), Colin Buckingham, Leesie Pinto, Tai’mua, Kang Frvr, Mollee Gray, Gallant, Maxwell Cunningham, Marcus Scribner and Ben Dickey.

    “In Starland” is produced by Panthaki and Daniel Khalili for Le Bateau Lavoir, Daisy Allsop for Archface Films and Victor Paul Wajnberg, and executive produced by Vachon and Plotts for Killer Films.

    The production was shot independently in Mississippi over 20 days, with Panthaki and his producing partners building the film outside the traditional studio system. Earlier this year, “In Starland” was selected as one of the BFI and British Council’s GREAT 8 at Cannes, the annual showcase spotlighting eight new UK feature films from first-time and early-career filmmakers to international buyers and festival programmers.

    “This film has been independent in the truest sense of the word. We took something already considered independent and stripped even that infrastructure away. There was no safety net, just a group of people who believed the film should exist and kept finding a way to make that happen,” said Panthaki.

    “That belief has carried us all the way through — in Clarence, in Daniel, in me, and ultimately in the film itself. So to be invited to world premiere at a festival like Tallinn, and close the first feature competition, is a huge honour.”

  • ‘Irresponsible and illegal’ first oral weight loss medicine ads banned by advertising watchdog

    ‘Irresponsible and illegal’ first oral weight loss medicine ads banned by advertising watchdog

    Some of the biggest online pharmacies in the UK have been found to have released ‘illegal and irresponsible’ advertisements related to weight loss pills.

    The Advertising Standards Agency, which regulates advertisements in the UK, has confirmed that the likes of Juniper, MedExpress, Simple Online Pharmacy and Pharmacy Online were all guilty of promoting unlicensed medicines and prescription-only medicines (POMs) to the public.

    Ever since the likes of Ozempic and Mounjaro became commonplace among celebrities, they have exploded in popularity with the general public, with many seeking out the GLP-1 medications as a seemingly quick and easy way of losing weight, despite the various side effects that have been associated with them.

    In the UK, Semaglutide and Tirzepatide medications such as Wegovy and Mounjaro are available through the NHS, but you’ll need to adhere to strict guidelines if you want to be eligible to receive them through the NHS.

    This led many flocking to the aforementioned online pharmacies, where it is worryingly easy to get your hands on a prescription, even if you’re nowhere near an unhealthy weight.

    When it was confirmed in June that the semaglutide (Wegovy) tablet had been approved by the MHRA, this process was likely to become even easier, with many who had a fear of self-injecting likely to feel much more at ease about taking a daily pill for their weight loss.

    The banned advert from Pharmacy Online (ASA)

    The banned advert from Pharmacy Online (ASA)

    However, Simple Online Pharmacy released an advertisement promoting it before it had even been approved, inviting customers to ‘join the waitlist’ for the controversial tablet.

    The ASA states: “The first oral GLP-1 tablet for weight management was licensed as a POM on 11 June 2026. Before that date, there was no UK marketing authorisation in place for these medicines.

    “Under the advertising rules, medicines must be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) before they can be promoted and medicinal claims cannot be made for an unauthorised medicine. Once a medicine is licensed as a POM, it cannot be advertised to the public.”

    Other pharmacies were also found to have broken the rules, with Pharmacy Online promoting the tablet through paid social advertisements, which are not permitted on TikTok or Instagram.

    It is illegal to promote POMs directly to consumers in the UK and yet nearly every online pharmacy seems to do it – we’ve probably all seen the adverts on TV and on the sides of our buses.

    MedExpress in particular have come under fire for their approach to advertising the PMOs (MedExpress/ASA)

    MedExpress in particular have come under fire for their approach to advertising the PMOs (MedExpress/ASA)

    While it is legal in the US, as we saw with Serena Williams’ controversial Super Bowl advert, the online pharmacies in the UK have to utilise people on social media, as LADbible discovered in an investigation last year, where dozens of influencers were found to have broken the law by including affiliate links to medications in their bios, and making their content entirely focused on the results of their own weight loss journeys.

    A quick look on TikTok reveals that this is still the case, despite the social media site’s guidelines stating: “Ad content and landing pages for dieting and weight management products must prioritise responsible claims and cannot promote such products as being the sole solution for weight loss or weight gain.

    “Any weight loss claims must target users aged 18 years or older, and must do so via the promotion of a healthy lifestyle.”

    Meanwhile, the ASA also made three further rulings against MedExpress, Juniper and the Care Pharmacy, which found that ads promoted POMs to the public, even though the medicines weren’t named directly.

    The ASA also made it clear that simply not naming a medicine is not enough to be legally compliant, as ‘imagery, language and claims, such as references to reducing cravings and appetite, significant weight loss or images of weight-loss injection pens’, were enough to see the ads from the aforementioned brands banned.

    Some pharmacies advertised the pill before it had even been approved for use in the UK (ASA/Simple Online Pharmacy)

    Some pharmacies advertised the pill before it had even been approved for use in the UK (ASA/Simple Online Pharmacy)

    The ASA said: “We know this remains a widespread and high-profile issue and we’re continuing to monitor ads and emerging trends in this area, working closely with our partners at the MHRA and the General Pharmaceutical Council (GPhC).

    “Weight loss prescription medicines are powerful treatments that should only be used under the supervision of a qualified medical professional. Advertising them irresponsibly or illegally can put people at risk, which is why this remains a priority for us.”

    This isn’t the first time that some of these online pharmacies have come under fire, with MedExpress in particular criticised for exploiting body insecurities in their previous adverts, while also coming under fire for using social media influencers to advertise their content – something which seemingly hasn’t changed.

    Catherine Drewett, Investigations Manager at the ASA concluded: “The licensing of oral GLP-1 medicines represents a significant development in treatment options but also new challenges for regulators. We’ve acted quickly as this market has developed and these first rulings make clear that these oral medicines, like prescription-only injections, cannot be advertised to the public. These are powerful medicines so it’s important that ads don’t encourage people to seek treatment in ways that could put them at risk”.

    LADbible has contacted Juniper, MedExpress, Simple Online Pharmacy and Pharmacy Online for comment, as well as one content creator who declined to comment.

  • ‘Line of Duty’ Creator Jed Mercurio Submits ‘Doctor Who’ Bid to BBC

    ‘Line of Duty’ Creator Jed Mercurio Submits ‘Doctor Who’ Bid to BBC

    “Line of Duty” creator Jed Mercurio has thrown his fedora in the ring to reboot the “Doctor Who” franchise.

    Mercurio, a prolific TV writer responsible for shows including Vicky McClure-starrer “Trigger Point” and “Bodyguard,” led by Richard Madden, has submitted his interest via Hat Trick Mercurio, the production company he co-founded with Jimmy Mulville.

    Last month the BBC launched a competitive tender inviting pitches from producers to reboot the series. The deadline for submitting interest was Friday, Oct. 2 with the BBC set to whittle down a shortlist of four to five prospective producers by Oct. 9, who will be asked to submit a “short editorial outline” for their vision for the new series.

    In its invitation to tender document setting out the process, the BBC said they are looking to award a contract to produce a “multi-episodic series” of the 63-year-old show including specials which they aim to broadcast in 2028/2029. The contract will include an option for a second season.

    Described as a “new flagship series of ‘Doctor Who,’” the broadcaster wants the reboot to feel “contemporary, and creatively ambitious, whilst remaining true to the values and characteristics that have made Doctor Who a beloved series across generations.”

    However, producers, who will also be required to develop a new “distinctive” companion for the show, will effectively be working for hire and will not own any rights to the series, which is almost entirely owned by the BBC. (The rights to the iconic Dalek cyborgs are split between the BBC and creator Terry Nation due to his agent crossing out the merchandising clause in his contract with the BBC in 1963). The BBC’s drama boss Lindsay Salt will be among those selecting the winning bidder, alongside commissioning editor Nick Lambon, business head for scripted Geraldine Atlee and business affairs manager James Dundas.

    Mercurio has long been known as a sci-fi fan and even co-authored a comic book, “Sleeper,” with Prasanna Puwanarajah which is set in the 24th century and centers around a biologically enhanced space marshall called DS-5. He also has a long and storied history with the BBC, with the series finale of “Line of Duty” becoming the most-watched U.K. drama of the century, racking up over 15 million views for the broadcaster in 2021.

    According to the BBC’s tender document, it is aiming to select a producing partner by March 2027.

    The BBC declined to comment. Hat Trick Mercurio did not respond to Variety’s queries.

  • Tether Hit With Lawsuit Over $2.76 Million Stablecoin Freeze

    Tether Hit With Lawsuit Over $2.76 Million Stablecoin Freeze

    In brief

    • Conduit sued Tether in New York federal court, alleging the stablecoin issuer froze $2.76 million in its treasury wallet on Sept. 24, 2025, without justification and has refused to release it.
    • The firm says a Brazilian police probe into a third party, Onix, was the backdrop, but its wallet was created after – Onix’s last transaction, never held Onix funds, and was flagged by Tether’s own unit—not police.
      Conduit says the freeze forced layoffs and office closures while Tether earned interest on the backing reserves.

    Cross-border payments company Conduit is taking Tether to court, alleging the stablecoin giant froze $2.76 million of its money without justification and has refused for more than a year to release it.

    In a complaint filed Monday in the U.S. District Court for the Southern District of New York, Conduit says Tether froze its treasury wallet, essentially the digital equivalent of its operating bank account, on Sept. 24, 2025, and has since kept the funds locked while profiting from the reserves backing them.

    Myriad: Where does Ethereum go next? Click to make your prediction.
    Myriad: Where does Ethereum go next? Click to make your prediction.

    The suit brings claims including conversion, unjust enrichment, breach of fiduciary duty and computer fraud, and demands the funds be returned.

    At the heart of the dispute is a Brazilian investigation that Conduit says has nothing to do with it. According to the filing, Brazil’s Federal Police were probing entities tied to a firm called Onix, which had once used Conduit’s platform.

    But Conduit says its frozen treasury wallet was created in May 2025, nearly a month after Onix’s last transaction on its platform, and never held any Onix funds. The company says the Federal Police confirmed they never flagged the wallet and don’t know what criteria Tether used to freeze it, pointing to Tether’s own T3 Financial Crime Unit as having made the call independently.

    BitcoinBTC · USD

    $83,714−1.83%

    Sep 30Oct 2Oct 4Oct 5Oct 7

    $86.8k$85.7k$84.6k$83.4k

    24h HighHigh$86,648

    24h LowLow$83,610

    VolVol$1.6B

    Market projectionsOdds by Myriad

    →

    Conduit argues the freeze has gutted its business. The wallet processed more than $1.1 billion in volume across roughly four months before being locked, and the company says the liquidity hit has forced it to lay off employees and close offices.

    Meanwhile, the company contends, Tether continues to earn interest on the U.S. Treasury securities backing the frozen tokens, “reaping the financial rewards” of the freeze at no cost to itself.

    The case adds to mounting scrutiny of Tether’s power to freeze USDT at will.

    Tether was separately sued this year over a $42.4 million freeze, and the company has frozen hundreds of millions in tokens flagged for illicit activity. Tether also recently joined Circle in freezing funds tied to the Bitget hack.

    Meanwhile, and somewhat ironically, the company has faced political heat for apparently not freezing enough. Sen. Richard Blumenthal recently called USDT a “superhighway” for sanctions evasion, pointing to Iran’s use of the stablecoin. Damned if you do, damned if you don’t.

    Daily Debrief Newsletter

    Start every day with the top news stories right now, plus original features, a podcast, videos and more.

  • Bitcoin’s recovery stalls just short of rescuing its last underwater cohort

    Bitcoin’s recovery stalls just short of rescuing its last underwater cohort

    Only one yearly bitcoin BTC$83,725.97 buyer cohort remains underwater, according to checkonchain data: investors who bought in 2025, with an average cost basis of approximately $88,000, which may now be forming a key resistance level due to sell pressure from relatively recent buyers.

    Bitcoin reached a monthly high of $87,500 in September before trading sideways and subsequently retreating below $84,000 as of Wednesday.

    These yearly volume-weighted cost bases have acted as support and resistance throughout the cycle. As bitcoin approaches a cohort’s average purchase price, some investors may look to exit at breakeven, while others may add to their positions.

    Bitcoin climbed to approximately $82,100 in May, matching the 2024 cohort’s average cost basis, before encountering resistance and falling back to $60,000. It eventually broke above that level in August.

    The 2023 cohort’s cost basis, currently around $65,000, has provided a recurring support level. When bitcoin fell towards $60,000 in February, that cohort’s cost basis was also near that level. It broadly held as support throughout the 2026 bear market, although bitcoin briefly traded below it.

  • ‘In the Shadows’ Producers to Self-Release British Boxing Biopic Following Collapse of U.K. Distributor True Brit Entertainment (EXCLUSIVE)

    ‘In the Shadows’ Producers to Self-Release British Boxing Biopic Following Collapse of U.K. Distributor True Brit Entertainment (EXCLUSIVE)

    The producers of upcoming British boxing biopic “In the Shadow” have successfully staged a last-minute rescue mission to save their film after its U.K. distributor True Brit Entertainment filed for administration in late September.

    The film — based on the true story of trailblazing British-Somali boxer, model and UNICEF Ambassador Ramla Ali and due to have its world premiere at the London Film Festival on Oct. 9 — will now be self-released theatrically in the U.K. thanks to additional support from its financiers.

    “We had to mobilize very quickly — it really was the 11th hour,” says Lee Magiday (a BAFTA winner and Oscar nominee for “The Favourite”), who produces alongside Madeleine Sanderson (“Being AP,” “Fighting for a City”). Magiday said they only found out in mid-September that there would be no money for the P&A spend. “So we had to ask our backers — our exec producers — whether they could put even more money into the film, which, thank God, they did.”

    Following it’s London Film Festival premiere, “In the Shadows” will now screen across the U.K. in more than 30 screens starting with a special screening and Q&A on Oct. 30 with Ali at London’s Genesis Cinema, near where the film was shot. With near perfect timing, Ali then has a world title fight on Nov. 8 in the U.S. and will return to help support the film with further special event screenings and Q&As.

    Magiday and Sanderson praise their exec producers Richard Fern, Anushka Shah and Natasha Mudhar for their additional financial support to enable the release, but also say they’re deeply thankful for the assistance of Will Clarke at Altitude Films, which is selling the “In the Shadows” globally. Clarke would introduce the producers to Ben Metcalf at Metis Films, which is now physically handling the distribution, with former True Brit exec Kate Neville-Towle overseeing marketing.

    “It’s really nice because a lot of people really love the film, love Ramla and love what we’re doing — so it’s a bit like a community,” says Sanderson. “We’ve got our team.”

    Led by “Top Boy” star Jasmine Jobson and directed by Anthony Wonke, “In the Shadow,” tells the story of refugee Ali, who, without the knowledge of her strictly Muslim parents in London, secretly pursued boxing to become the first Somali-British professional boxing champion. It was at the boxing club where she trained that she met her future husband, Richard Moore, who converted to Islam — a testament to his profound love for her. The film explores both Ali’s drive to succeed despite the numerous obstacles in and out of the ring — a drive that helped her become the first boxer ever to represent Somalia at the the 2020 Olympic Games and the first-ever professional female boxing match in Saudi Arabia — and the love story between her and Moore as they navigate racial and cultural barriers.

    For Magiday, there are parallels between the story behind “In the Shadows” and the making of it, culminating in the last-minute rescue.

    “This film has been a battle from day one and and Ramla’s story has been a battle from day one, so it’s kind of in keeping,” she said. “We’ve had to kind of fight the odds the whole time because we didn’t get industry support for production. This was made by sheer will and determination, and some amazing backers who believed in the story. For us, it’s such an important film because it is about hope. It’s not just the normal boxing story — it’s about being accepted by your your culture, by your family, by your community, and also finding love.”

    See the “In the Shadows” trailer below

  • US Government Wallets Activity Increases, Bitcoin Falls! Which Level Should Be Defined for the Uptrend to Continue? Analysts Explain

    US Government Wallets Activity Increases, Bitcoin Falls! Which Level Should Be Defined for the Uptrend to Continue? Analysts Explain

    $101 Million Worth of Crypto Transferred from US Government-Linked Wallets!

    A noticeable surge in cryptocurrency wallets linked to the US government has been observed. According to the on-chain tracking platform Lookonchain, Bitcoin and $BNB totaling approximately $103 million were transferred from government-linked addresses.

    At this point, the US government completed Bitcoin transfers exceeding $70 million last night and $BNB transfers this morning.

    Bitcoin accounted for the largest portion of the transfers. A US-linked address sent 833.6 $BTC, worth approximately $71 million, to Coinbase Prime.

    During the same process, approximately 40,285 $BNB, worth about $31.63 million, were also transferred. Unlike Bitcoin, $BNB was sent to an unknown address after multiple transfers.

    The wallets still contain approximately $27.5 billion worth of cryptocurrencies.

    Is a Bitcoin Sell Coming?

    While the transfer to Coinbase Prime has raised questions about a possible sale in the market, current data does not indicate that such a sale occurred. Furthermore, the transfer alone does not mean the Bitcoins were sold. The platform offers asset management services to institutional investors, in addition to custody and transaction services. Therefore, to determine whether a sale took place, the subsequent movements of the $BTC in question need to be monitored.

    What’s the Latest Situation with Bitcoin?

    With these developments increasing selling pressure on Bitcoin, analysts are pointing to the $83,000 level.

    Speaking to CoinDesk, Vikram Subburaj, CEO of the cryptocurrency exchange Giottus, stated that it is important for Bitcoin to remain above the $83,000 level. According to Subburaj, maintaining this level means that selling pressure is not yet strong enough to pull Bitcoin back down to the $76,000-$81,500 range. However, if Bitcoin remains permanently below the $82,000-$83,000 levels, it could increase downside risks. In such a scenario, Subburaj indicated that the price could fall to the $80,000-$81,500 range.

    Alex Kuptsikevich, chief market analyst at FxPro, considers $84,000 a significant support level for Bitcoin. According to the analyst, a drop below this level could lead to increased selling pressure and pull the price down towards $80,000.

    *This is not investment advice.

  • Here’s what bitcoin needs to break above $87,000

    “I read the current move as evidence that the ETF bid that carried September has not yet returned strongly enough to offset renewed macro pressure. ETF inflows above roughly $300 million a session for several sessions (my threshold rather than a market one) would be an important signal that institutional demand is returning,” Oliver Carding, head of marketing at Tesseract Group, said in an email.

    Martin Lee, head of content and data insights at DWF Labs, said large daily inflows matter more than extended inflow streaks that cumulatively bring in only a few hundred million dollars.

    “Looking across the year, we’ve had 93 out of 190 (48%) trading days be negative while still seeing net $1.2B of inflows. Longer-term (week/month) size of flows is more important compared to daily, which is almost a coin flip this year, but definitely something worth monitoring to see how the situation progresses,” he said.

    Meanwhile, other types of buyers are accumulating.

    “Investors appear to be using periods of weakness to accumulate and dollar-cost average alongside institutional buyers,” Paul Howard, senior director at Wincent, said. “Many market participants are continuing to target Bitcoin at $100k+.” Stay alert!

    Read more: For analysis of today’s activity in altcoins and derivatives, see Crypto Markets Today. For a comprehensive list of events this week, see CoinDesk’s Crypto Week Ahead.